statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and...

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled...

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Vanguard Group Inc. reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 0.1% in the 3rd quarter, according to its most recent filing with the Securities and...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Vanguard Group Inc.

A month has gone by since the last earnings report for Ligand Pharmaceuticals (LGND). Shares have lost about 15.5% in that time frame, underperforming the S&P 500.Will the recent negative trend...

Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?

Pacer Advisors Inc. lifted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND  Free Report) by 59.1% during the 4th quarter, according to the company in its most recent filing...

Pacer Advisors Inc. Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Nordea Investment Management AB lessened its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND  Free Report) by 3.3% in the 4th quarter, according to its most recent filing with...

Nordea Investment Management AB Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

LGND's total volume now sits at 1.2M. The +-1.17% price change was insignificant, leaving IBM's price at $71.09...

The volume for Ligand Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 664% of the 65-Day Volume Moving Average

This indicator may be signaling that LGND's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Ligand Pharmaceuticals (LGND, $72.47) entered Downtrend as Momentum indicator drops below 0 level on Mar 07, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the...

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND  Get Free Report) CFO Octavio Espinoza sold 140 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, February 28th. The shares...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Sells $12,384.40 in Stock

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Volume	9,522.00
52-Wk High	$94.57
52-Wk Low	$49.24

LGND Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

About

Feed

News

Sentiment

Earnings

Fundamentals